Efficacy Study of Botulinum Toxin (BOTOX) Injections to Treat Vocal Fold Granulomas

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

WITHDRAWN

Clinical Phase

PHASE2

Study Classification

INTERVENTIONAL

Study Start Date

2012-09-30

Study Completion Date

2015-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Vocal process granulomas are inflammatory masses caused in part by vocal trauma that arise in the posterior aspect of the vocal folds and result in throat pain, difficulty swallowing, hoarseness, and globus sensation. Antireflux therapy treats most granulomas, but many are recalcitrant to this therapy or take months to years to resolve. Botulinum toxin injection into the thyroarytenoid muscle has been effectively employed for recalcitrant granuloma, but causes significant voice loss, occasional difficulty swallowing and, in our clinical experience, is associated with significant recurrence. The investigators propose injecting another muscle in the larynx called the interarytenoid muscle with botulinum toxin type A to maintain the benefit of injection with less loss of voice. The investigators have shown the effectiveness of this treatment in a small, retrospective analysis.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

BOTOX® Drug Use Investigation (Spasmodic Dysphonia)

NCT03543150

Dysphonia

UNKNOWN

Firdapse for Post-BOTOX Vocal Weakness

NCT05123053

Vocal Weakness(Post-BOTOX Injection)

COMPLETED PHASE2

INNOVATIVE TREATMENT OF SCARRED VOCAL FOLDS BY LOCAL INJECTION OF AUTOLOGOUS ADIPOSE-DERIVED STROMAL VASCULAR FRACTION: EFFICACY VERSUS PLACEBO

NCT05385159

Scarred Vocal Folds

UNKNOWN PHASE2

Essential Voice Tremor: A Study of Botulinum Toxin Treatment and Injection Augmentation

NCT02711995

Essential Tremor

COMPLETED NA

Onabotulinum Toxin A (Botox) in the Treatment of Transfer Dysphagia

NCT04695600

Transfer Dysphagia Oropharyngeal Dysphagia Cricopharyngeus Muscle Dysfunction +1 more

UNKNOWN PHASE2/PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Vocal fold granulomas may be due to reflux, voice trauma, intubation, multiple or unknown etiologies. Regimens of voice therapy and anti-reflux medications have show resolution rates varying from 38% to 100%, with recurrence rates of 15-20%, and up to 50-92% in surgical-operated on recalcitrant granulomas. Nasri and colleagues first proposed thyroarytenoid botulinum toxin type A (BOTOX) injections for vocal fold granulomas with success. They posited that the chemically paralyzed muscle would result in limited contact at the site of the granuloma, allowing for healing. Damrose and Damrose further showed that thyroarytenoid BOTOX injections were effective in treating recalcitrant vocal fold granulomas. Both of the above groups noted hoarseness as an expected side effect. Pham and colleagues showed complete resolution of granulomas in 2-8 weeks after treatment with thyroarytenoid BOTOX injections. This was compared to mean granuloma resolution of 5.7 months proton pump inhibitor therapy alone. The investigators reviewed eight patients treated for recalcitrant vocal fold granuloma at Mass Eye and Ear with interarytenoid BOTOX injections and found no serious adverse effects and complete response in seven cases. The investigators now seek to compare interarytenoid BOTOX injections to standard anti-reflux therapy alone to see if the addition of IA Botox injections improves response rates at 3 months. The investigators chose this timeframe since 86% of granulomas treated in our retrospective study had resolved 3 months after initiation of treatment compared to 25% of granulomas treated with medical management.

The investigators will not include a Thyroarytenoid injection arm in this study as this technique has not been useful in our clinical experience.

For those who consent, a Voice Handicap Index survey (6 - see attached) will be completed. Participants will then be randomized to undergo only medical therapy with omeprazole (40mg by mouth twice daily ) or an interarytenoid BOTOX injection followed by the same reflux regimen. Randomization will be performed by the Tufts online randomization plan, which may be found at: http://www.tufts.edu/\~gdallal/PLANDOC.HTM. This program generates a random order in which participants will be enrolled in either of the two arms of the study.

The injection will consist of 10 units of botulinum toxin injected into the interarytenoid muscle under fiberoptic visualization. All participants will remain on the PPI therapy for the duration of the study. Participants will receive prescriptions for PPI medication from the attending Laryngologist and participants will then be responsible for acquiring and taking their medications.

Injections will be performed per standard MEEI Laryngology protocol for interarytenoid BOTOX injection. Participants will then be evaluated at 1.5 months, 3 months and 6 months with fiberoptic examination as well as Voice Handicap Index \& Reflux Symptom Index. Participants in the medication only arm who continue to have a granuloma at 3 months will receive a BOTOX injection. They will be re-evaluated 3 months after the injection. Examinations will be recorded and reviewed by blinded reviewers.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Contact Ulcer of Vocal Folds Granuloma of Vocal Cords Granuloma, Laryngeal Granuloma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

PPI and BOTOX

onabotulinumtoxinA (BOTOX), injection, 10 units, one time; omeprazole 40mg po bid (standard of care) for 3 months

Group Type EXPERIMENTAL

onabotulinumtoxinA

Intervention Type DRUG

Botulinum toxin A is injected into the larynx in order to treat vocal fold granulomas.

omeprazole (proton pump inhibitor)

Intervention Type DRUG

Standard therapy of anti-reflux medications using omeprazole or equivalent PPI.

Proton pump inhibitor only

omeprazole 40mg po bid for 3 months(standard of care)

Group Type OTHER

omeprazole (proton pump inhibitor)

Intervention Type DRUG

Standard therapy of anti-reflux medications using omeprazole or equivalent PPI.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

onabotulinumtoxinA

Botulinum toxin A is injected into the larynx in order to treat vocal fold granulomas.

Intervention Type DRUG

omeprazole (proton pump inhibitor)

Standard therapy of anti-reflux medications using omeprazole or equivalent PPI.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

BOTOX Botulinum toxin A omeprazole

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* adults age 18 years old and older with vocal fold granulomas
* willing to attend all follow-up appointments

Exclusion Criteria

* pregnant females
* woman who are nursing
* minors and other patients unable to give informed consent
* patients taking Plavix
* patients with:
* impaired laryngeal motion as the result of neurological impairment
* vocal fold immobility
* pre-existing oropharyngeal swallowing problems
* history of radiation therapy
* history of aspiration pneumonia

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No